Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications

Csaba Szabo

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Activation of poly(ADP-ribose) polymerase (PARP) plays a role in the pathogenesis of β-cell necrosis that occurs in response to autoimmune disease associated with Type I diabetes. In addition, PARP activation also plays a role in the pathogenesis of endothelial injury that underlies the ethiology of various diabetic complications (vasculopathy, cardiomyopathy, retinopathy, neuropathy), which develop on the basis of chronically elevated circulating glucose levels in diabetes. Both during the pathogenesis of diabetes and during the pathogenesis of diabetic complications, free radical and oxidant production leads to DNA strand-breakage which activates the nuclear enzyme PARP and initiates an energy consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. These processes lead to the functional impairment of the affected cells (β-cells or vascular endothelial cells, respectively). PARP also promotes the activation of various pro-inflammatory signal transduction pathways. During the last two decades, a growing number of experimental studies demonstrated the beneficial effects PARP inhibition in various models of diabetes and diabetic complications. The current review provides an overview of the experimental evidence implicating PARP as a causative factor in the pathogenesis of diabetes and diabetic complications in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)60-71
Number of pages12
JournalPharmacological Research
Volume52
Issue number1 SPEC. ISS.
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Diabetes Complications
Type 1 Diabetes Mellitus
Cardiomyopathies
Oxidants
NAD
Adenosine Diphosphate
Autoimmune Diseases
Free Radicals
Signal Transduction
Necrosis
Endothelial Cells
Glucose
DNA
Wounds and Injuries
Enzymes
Proteins

Keywords

  • Cardiomyopathy
  • Cytokines
  • Diabetes
  • Endothelium
  • Kidney
  • Neuropathy
  • Nitric oxide
  • Oxidative stress
  • Peroxynitrite
  • Poly(ADP-ribose) polymerase
  • Retina

ASJC Scopus subject areas

  • Pharmacology

Cite this

Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. / Szabo, Csaba.

In: Pharmacological Research, Vol. 52, No. 1 SPEC. ISS., 07.2005, p. 60-71.

Research output: Contribution to journalArticle

@article{01be41007bc64566a7d447d10de652e4,
title = "Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications",
abstract = "Activation of poly(ADP-ribose) polymerase (PARP) plays a role in the pathogenesis of β-cell necrosis that occurs in response to autoimmune disease associated with Type I diabetes. In addition, PARP activation also plays a role in the pathogenesis of endothelial injury that underlies the ethiology of various diabetic complications (vasculopathy, cardiomyopathy, retinopathy, neuropathy), which develop on the basis of chronically elevated circulating glucose levels in diabetes. Both during the pathogenesis of diabetes and during the pathogenesis of diabetic complications, free radical and oxidant production leads to DNA strand-breakage which activates the nuclear enzyme PARP and initiates an energy consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. These processes lead to the functional impairment of the affected cells (β-cells or vascular endothelial cells, respectively). PARP also promotes the activation of various pro-inflammatory signal transduction pathways. During the last two decades, a growing number of experimental studies demonstrated the beneficial effects PARP inhibition in various models of diabetes and diabetic complications. The current review provides an overview of the experimental evidence implicating PARP as a causative factor in the pathogenesis of diabetes and diabetic complications in vitro and in vivo.",
keywords = "Cardiomyopathy, Cytokines, Diabetes, Endothelium, Kidney, Neuropathy, Nitric oxide, Oxidative stress, Peroxynitrite, Poly(ADP-ribose) polymerase, Retina",
author = "Csaba Szabo",
year = "2005",
month = "7",
doi = "10.1016/j.phrs.2005.02.015",
language = "English (US)",
volume = "52",
pages = "60--71",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "1 SPEC. ISS.",

}

TY - JOUR

T1 - Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications

AU - Szabo, Csaba

PY - 2005/7

Y1 - 2005/7

N2 - Activation of poly(ADP-ribose) polymerase (PARP) plays a role in the pathogenesis of β-cell necrosis that occurs in response to autoimmune disease associated with Type I diabetes. In addition, PARP activation also plays a role in the pathogenesis of endothelial injury that underlies the ethiology of various diabetic complications (vasculopathy, cardiomyopathy, retinopathy, neuropathy), which develop on the basis of chronically elevated circulating glucose levels in diabetes. Both during the pathogenesis of diabetes and during the pathogenesis of diabetic complications, free radical and oxidant production leads to DNA strand-breakage which activates the nuclear enzyme PARP and initiates an energy consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. These processes lead to the functional impairment of the affected cells (β-cells or vascular endothelial cells, respectively). PARP also promotes the activation of various pro-inflammatory signal transduction pathways. During the last two decades, a growing number of experimental studies demonstrated the beneficial effects PARP inhibition in various models of diabetes and diabetic complications. The current review provides an overview of the experimental evidence implicating PARP as a causative factor in the pathogenesis of diabetes and diabetic complications in vitro and in vivo.

AB - Activation of poly(ADP-ribose) polymerase (PARP) plays a role in the pathogenesis of β-cell necrosis that occurs in response to autoimmune disease associated with Type I diabetes. In addition, PARP activation also plays a role in the pathogenesis of endothelial injury that underlies the ethiology of various diabetic complications (vasculopathy, cardiomyopathy, retinopathy, neuropathy), which develop on the basis of chronically elevated circulating glucose levels in diabetes. Both during the pathogenesis of diabetes and during the pathogenesis of diabetic complications, free radical and oxidant production leads to DNA strand-breakage which activates the nuclear enzyme PARP and initiates an energy consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. These processes lead to the functional impairment of the affected cells (β-cells or vascular endothelial cells, respectively). PARP also promotes the activation of various pro-inflammatory signal transduction pathways. During the last two decades, a growing number of experimental studies demonstrated the beneficial effects PARP inhibition in various models of diabetes and diabetic complications. The current review provides an overview of the experimental evidence implicating PARP as a causative factor in the pathogenesis of diabetes and diabetic complications in vitro and in vivo.

KW - Cardiomyopathy

KW - Cytokines

KW - Diabetes

KW - Endothelium

KW - Kidney

KW - Neuropathy

KW - Nitric oxide

KW - Oxidative stress

KW - Peroxynitrite

KW - Poly(ADP-ribose) polymerase

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=19444377566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444377566&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2005.02.015

DO - 10.1016/j.phrs.2005.02.015

M3 - Article

C2 - 15911334

AN - SCOPUS:19444377566

VL - 52

SP - 60

EP - 71

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1 SPEC. ISS.

ER -